^
Association details:
| Biomarker: | FOLR1 expression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + luveltamab tazevibulin (STRO-002) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers
Published date:
11/30/2022
Excerpt:
A single dose of STRO-002 induced significant tumor growth inhibition in FolRα-expressing xenograft models and patient-derived xenograft models. In addition, combination treatment with carboplatin or Avastin further increased STRO-002 efficacy in xenograft models. The potent and specific preclinical efficacy of STRO-002 supports clinical development of STRO-002 for treating patients with FolRα-expressing cancers, including ovarian, endometrial, and non–small cell lung cancer.
Secondary therapy:
carboplatin
DOI:
10.1158/1535-7163.MCT-22-0322
